Onasemnogene Abeparvovec
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Onasemnogene Abeparvovec: From Spinal Muscular Atrophy to Bronchitis
One-Sentence Summary
Onasemnogene abeparvovec is an AAV9-vectored gene therapy that delivers a functional SMN1 gene, approved for spinal muscular atrophy (SMA). The TxGNN model’s top prediction is possible efficacy in Bronchitis, but this is currently supported by 0 clinical trials and 0 publications — and the evidence pack itself flags the prediction as a likely false positive with no biological plausibility.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Spinal Muscular Atrophy (SMA) — noted in evidence rationale; structured licence data not available |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 86.13% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for onasemnogene abeparvovec (data gap). Based on known information, this product is an AAV9 vector-based gene therapy that delivers a functional copy of SMN1 to restore survival motor neuron protein expression, and its efficacy has been established in SMA — a neuromuscular disorder.
Unlike the SMA indication, bronchitis is an airway inflammatory/infectious condition with no known pathophysiological connection to motor neuron survival or SMN1 gene replacement. The evidence pack’s own rationale is explicit on this point: there is no known mechanism linking SMN1 gene replacement therapy to bronchitis, and the prediction is most likely an artefact of knowledge-graph embedding proximity rather than a biologically grounded signal. No clinical trials, ICTRP trials, or literature exist to support drug-disease association for this pairing.
The same pattern holds across the other nine predictions in this evidence pack (diabetic retinopathy, bronchial and testicular neoplasms, hamartoma, ductular proliferation, etc.) — all are rated L5/Hold, and none have a stated mechanistic rationale. One entry (ductal/ductular proliferation, rank 8) returned 20 PubMed hits, but these are hepatic fibrosis/cholestasis mechanism papers that do not mention onasemnogene abeparvovec or AAV9 gene therapy at all, so they do not constitute drug-specific evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
Onasemnogene abeparvovec is not currently registered on the ARTG (0 entries) and has a market status of “not marketed” in Australia.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This is a pure model prediction (L5) with no supporting clinical trials or literature, and the evidence pack itself assesses the drug–disease link as biologically implausible and likely a knowledge-graph false positive.
To proceed, the following is needed:
- TGA-approved Product Information — key warnings and contraindications (currently a blocking data gap)
- Detailed mechanism of action data from DrugBank/manufacturer sources
- Any drug-specific preclinical or case evidence for a respiratory indication, should new data emerge
- Re-evaluation only if independent mechanistic or clinical evidence for bronchitis appears — not recommended for further pipeline advancement based on current evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.